Growth inhibition of mammalian cells by eosinophil cationic protein.

Eosinophil cationic protein (ECP), one of the major components of basic granules of eosinophils, is cytotoxic to tracheal epithelium. However, the extent of this effect on other cell types has not been evaluated in vitro. In this study, we evaluated the effect of ECP on 13 mammalian cell lines. ECP inhibited the growth of several cell lines including those derived from carcinoma and leukemia in a dose-dependent manner. The IC(50) values on A431 cells, MDA-MB-453 cells, HL-60 cells and K562 cells were estimated to be approximately 1-5 microm. ECP significantly suppressed the size of colonies of A431 cells, and decreased K562 cells in G1/G0 phase. However, there was little evidence that ECP killed cells in either cell line. These effects of ECP were not enhanced by extending its N-terminus. Rhodamine B isothiocyanate-labeled ECP started to bind to A431 cells after 0.5 h and accumulated for up to 24 h, indicating that specific affinity for the cell surface may be important. The affinity of ECP for heparin was assessed and found to be reduced when tryptophan residues, one of which is located at a position in the catalytic subsite of ribonuclease in ECP, were modified. The growth-inhibitory effect was also attenuated by this modification. These results suggest that growth inhibition by ECP is dependent on cell type and is cytostatic.

[1]  M. Seno,et al.  Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. , 2001, Biochemistry.

[2]  J. Pous,et al.  Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution. , 2000, Journal of molecular biology.

[3]  M. Seno,et al.  Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. , 2000, Cytokine.

[4]  E. Boix,et al.  Crystal structure of eosinophil cationic protein at 2.4 A resolution. , 1999, Biochemistry.

[5]  Jianzhi Zhang,et al.  Rapid Evolution of the Ribonuclease A Superfamily: Adaptive Expansion of Independent Gene Clusters in Rats and Mice , 1999, Journal of Molecular Evolution.

[6]  M. Seno,et al.  Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. , 1999, Protein engineering.

[7]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[8]  M. Lindsay,et al.  Pharmacology of the eosinophil. , 1999, Pharmacological reviews.

[9]  D. Newton,et al.  Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth. , 1998, Journal of the National Cancer Institute.

[10]  M. Seno,et al.  Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. , 1998, Protein engineering.

[11]  I. Pastan,et al.  Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. , 1998, Trends in biotechnology.

[12]  H. Rosenberg,et al.  The eosinophil ribonucleases , 1998, Cellular and Molecular Life Sciences CMLS.

[13]  K. Dyer,et al.  Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity. , 1997, Nucleic acids research.

[14]  M. Seno,et al.  Tissue-specific expression of pancreatic-type RNases and RNase inhibitor in humans. , 1997, DNA and cell biology.

[15]  M. Libonati,et al.  Structure–function relationships in human ribonucleases: main distinctive features of the major RNase types , 1997, FEBS letters.

[16]  E. Olson,et al.  Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Prochiantz,et al.  Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.

[18]  M. Seno,et al.  Recombinant human pancreatic ribonuclease produced in E. coli: importance of the amino-terminal sequence. , 1995, Biochemical and biophysical research communications.

[19]  H. Rosenberg Recombinant Human Eosinophil Cationic Protein , 1995, The Journal of Biological Chemistry.

[20]  M. Seno,et al.  Nucleotide sequence encoding human pancreatic ribonuclease. , 1994, Biochimica et biophysica acta.

[21]  B. Geiger,et al.  Suppression of vinculin expression by antisense transfection confers changes in cell morphology, motility, and anchorage-dependent growth of 3T3 cells , 1993, The Journal of cell biology.

[22]  M. Kanehisa,et al.  A knowledge base for predicting protein localization sites in eukaryotic cells , 1992, Genomics.

[23]  B. Geiger,et al.  Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA , 1992, The Journal of cell biology.

[24]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[25]  R. L. Barker,et al.  In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. , 1990, Journal of immunology.

[26]  R. L. Barker,et al.  Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. , 1989, Journal of immunology.

[27]  T. Ganz,et al.  Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. , 1989, Journal of immunology.

[28]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.

[29]  R. Dahl,et al.  Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  H. Jörnvall,et al.  Purification and characterization of eosinophil cationic protein from normal human eosinophils , 1988, European journal of haematology.

[31]  G. Gleich,et al.  Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. , 1988, The American journal of tropical medicine and hygiene.

[32]  T. Hiratsuka Selective fluorescent labeling of the 50-, 26-, and 20-kilodalton heavy chain segments of myosin ATPase. , 1987, Journal of biochemistry.

[33]  R. L. Barker,et al.  Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. , 1987, The Journal of parasitology.

[34]  M. Yazdanbakhsh,et al.  Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni. , 1987, Journal of immunology.

[35]  J. Tavernier,et al.  Killing of Plasmodium falciparum by eosinophil secretory products , 1987, Infection and immunity.

[36]  D. Loegering,et al.  Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. , 1986, Journal of immunology.

[37]  P. Venge,et al.  Mechanism of membrane damage mediated by human eosinophil cationic protein , 1986, Nature.

[38]  D. Loegering,et al.  Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Loegering,et al.  Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. , 1985, The American journal of tropical medicine and hygiene.

[40]  R. Dahl,et al.  The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. , 1982, The Journal of allergy and clinical immunology.

[41]  I. Olsson,et al.  Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro , 1981, Parasite immunology.

[42]  E. Ben-hur,et al.  Characterization of the response of a human breast carcinoma cell line (T-47D) to radiation and chemotherapeutic agents. , 1981, Israel journal of medical sciences.

[43]  J. Bertram,et al.  Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. , 1980, Cancer letters.

[44]  S. M. Sumi,et al.  Neurotoxicity of human eosinophils. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Gahmberg,et al.  K562—A human erythroleukemic cell line , 1979, International journal of cancer.

[46]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.

[47]  S. von Kleist,et al.  Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. , 1975, Journal of the National Cancer Institute.

[48]  F. O'Neill Control of nuclear division in SV40 and adenovirus type 12 transformed mouse 3T3 cells , 1975, International journal of cancer.

[49]  S. Aaronson,et al.  Development of 3T3‐like lines from Balb/c mouse embryo cultures: Transformation susceptibility to SV40 , 1968, Journal of cellular physiology.

[50]  N. Green,et al.  The reactivity toward N-bromosuccinimide of tryptophan in enzymes, zymogens, and inhibited enzymes. , 1966, Biochemistry.

[51]  G. Waksman,et al.  Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. , 2001, Cancer research.

[52]  M. Desantis,et al.  Purification and characterization of a recombinant human cripto-1 protein. , 1998, Growth factors.

[53]  S. Brunak,et al.  SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .

[54]  J. Folkman,et al.  Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. , 1996, Growth factors.

[55]  D. Pardoll Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.